Patients with coronary artery disease (CAD) often have normal blood cholesterol profiles that make it difficult to identify those at risk. The role of lipoprotein subfractions in the development of CAD has attracted increasing attention, and can further stratify risks. We enrolled 1578 patients undergoing coronary angiography and not taking any lipid-lowering drugs; 1033 of them were diagnosed with CAD. The severity of CAD was assessed using Gensini score (GS) and divided into 3 groups. Multivariate regression analysis showed that low-density lipoprotein particle 6 (LDL-P6) and lipoprotein (a) (Lp(a)) were independent risk factors for CAD, apart for the traditional risk factors. In receiver-operating characteristic (ROC) analysis for predicting the presence of CAD, the area under the ROC curve of traditional risk factors combined with Lp(a) and LDL-P6 for predicting CAD was .723, which was better than for traditional risk factors (P = .023). The plasma LDL-P6 and Lp(a) concentrations in the highest tertile GS group were significantly higher than that in the lowest GS group (P < .001). Stepwise linear regression analysis demonstrated positive correlations between Lp(a), LDL-P6 and GS (P = .007 and P < .001). LDL-P6 and Lp(a) are useful markers for predicting the presence and severity of CAD.
ViraniSSAlonsoABenjaminEJ, et al.Heart disease and stroke statistics-2020 update: a report from the American heart association. Circulation. 2020;141:e139-596.
2.
BarqueraSPedroza-TobíasAMedinaC, et al.Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res. 2015;46:328-38.
3.
HuSSChenYHGaoRL, et al.The writing committee of the report on cardiovascular health and diseases in China: report on cardiovascular health and diseases in China 2019: an updated summary. Chinese Circulation J. 2020;35:833-54.
4.
KaveyREMietus-SnyderM. Beyond cholesterol: the atherogenic consequences of combined dyslipidemia. J Pediatr. 2012;161:977-9.
5.
OtvosJD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab. 2002;48:171-80.
6.
MoraSBuringJERidkerPM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation. 2014;129:553-61.
7.
JeyarajahEJCromwellWCOtvosJD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26:847-70.
8.
GensiniGG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51:606.
9.
FinegoldJAAsariaPFrancisDP. Mortality from ischaemic heart disease by country, region, and age: statistics from world health organisation and united nations. Int J Cardiol. 2013;168:934-45.
10.
SampsonUKFazioSLintonMF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14:1-10.
11.
SachdevaACannonCPDeedwaniaPC, et al.Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136, 905 hospitalizations in Get With The Guidelines. Am Heart J. 2009;157:111-7. e112.
12.
BucherHCRichterWGlassTR, et al.Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2012;60:135-42.
13.
AraiHKokuboYWatanabeM, et al.Small dense low-density lipoproteins cholesterol can predict incident cardiovascular disease in an urban Japanese cohort: the Suita study. J Atheroscler Thromb. 2013;20:195-203.
14.
IpSLichtensteinAHChungM, et al.Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann Intern Med. 2009;150:474-484.
15.
LangloisMRChapmanMJCobbaertC, et al.Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus statement from EAS and EFLM. Clin Chem. 2018;64:1006–33.
16.
KraussRM. Dietary and genetic effects on low-density lipoprotein heterogeneity. Annu Rev Nutr. 2001;21:283-95.
17.
SuperkoHRGadesamRR. Is it LDL particle size or number that correlates with risk for cardiovascular disease?Curr Atheroscler Rep. 2008;10:377-85.
18.
MikhailidisDPElisafMRizzoM, et al.European panel on low density lipoprotein (LDL) subclasses: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9:533-71.
19.
SuperkoHR. Advanced lipoprotein testing and subfractionation are clinically useful. Circulation. 2009;119:2383-2395.
20.
BlakeGJOtvosJDRifaiN, et al.Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 2002;106:1930-7.
21.
OtvosJDCollinsDFreedmanDS, et al.Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial. Circulation. 2006;113:1556-63.
22.
AustinMARodriguezBLMcKnightB, et al.Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am J Cardiol. 2000;86:412-6.
23.
LamarcheBTchernofAMoorjaniS, et al.Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation. 1997;95:69-75.
24.
KathiresanSOtvosJDSullivanLM, et al.Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation. 2006;113:20-9.
25.
BorénJWilliamsKJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol. 2016;27:473-83.
26.
SteinbergD. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002;8:1211-7.
27.
BennetADi AngelantonioEErqouS, et al.Lipoprotein(a) levels and risk of future coronary heart disease: Large-scale prospective data. Arch Intern Med. 2008;168:598-608.
28.
VarvelSMcConnellJPTsimikasS. Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States. Arterioscler Thromb Vasc Biol. 2016;36:2239-45.
29.
TsimikasS. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69:692-711.
30.
Reyes-SofferGGinsbergHNBerglundL, et al.American heart association council on arteriosclerosis, thrombosis and vascular biology; council on cardiovascular radiology and intervention; and council on peripheral vascular disease. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart association. Arterioscler Thromb Vasc Biol. 2022;42:e48-60.
